As showed in Table 2, when all eligible studies were pooled into the meta-analysis, we found that the XPF-rs1800067 polymorphism was not significantly associated with overall cancer risk, with a statistical power of 98% (homozygous model: OR = 1.21, 95% CI = 0.73–1.99, P = 0.020 for heterogeneity test, I2 = 45.2%; recessive model: OR = 1.20, 95% CI = 0.73–1.98, P = 0.022 for heterogeneity test, I2 = 44.6%). Here, ERCC4 is linked to cancer.